Document:

Exhibit 10.2 

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY
NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM,
THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. 

 

_______________________________

 

BIONIK LABORATORIES CORP.

 

CONVERTIBLE PROMISSORY NOTE

 

	Principal Amount: US$[_____]	Issue Date: [_____]

 

Bionik
Laboratories Corp., a Delaware corporation (the “Company”), for value received, hereby promises
to pay to [_____] or his permitted assigns or successors (the “Holder”), the principal amount of [_____]
Dollars (US$[___]) (the “Principal Amount”), without demand, on the Maturity Date (as hereinafter defined),
together with any accrued and unpaid interest due thereon. This Note shall bear interest at a fixed rate of 1% per month, beginning
on the Issue Date. Interest shall be computed based on a 360-day year of twelve 30-day months and shall be payable, along with
the Principal Amount, on the Maturity Date. Except as set forth in Section 3.1, payment of all principal and interest due
shall be in such coin or currency of the United States of America as shall be legal tender for the payment of public and private
debts at the time of payment.

 

This Note is a convertible
promissory note referred to in that certain Subscription Agreement dated as of the date hereof, or series of like subscription
agreements (individually or collectively, the “Subscription Agreement”), among the Company and the subscribers
named therein, pursuant to which the Company is seeking to borrow up to $6,000,000 (the “Offering”).

 

1.       Definitions.

 

1.1       Definitions.
The terms defined in this Section 1 whenever used in this Note shall have the respective meanings hereinafter specified.

 

“Change
in Control”  means a merger or consolidation of the Company with or into any other entity in which the stockholders
of the Company immediately prior to the merger or consolidation do not own more than 50% of the outstanding voting power (assuming
conversion of all convertible securities and the exercise of all outstanding options and warrants) of the surviving entity or the
sale, lease, licensing, transfer or other disposition of all or substantially all the assets of the Company; provided, however,
that any new issuance of capital stock (or securities convertible or exercisable into capital stock) of the Company to one or more
third parties for the sole purpose of providing funding for the Company shall not constitute a Change in Control.

 

“Common
Stock” means the common stock, par value $0.001 per share, of the Company.

 

    1 

     

    

 

“Conversion
Shares” means the New Round Stock issued or issuable to the Holder pursuant to Article 3.

 

“Event
of Default” shall have the meaning set forth in Section 6.1.

 

“Holder”
or “Holders” means the person named above or any Person who shall thereafter become a recordholder of
this Note in accordance with the terms hereof.

 

“Issue
Date” means the issue date stated above.

 

“Maturity
Date” shall mean the earlier of: (a) July 20, 2018 and (b) the consummation of a Qualified Financing.

 

“New Round
Stock” means Common Stock.

 

“Note”
means this Convertible Note, as amended, modified or restated.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, joint venture, unincorporated organization
or any government, governmental department or agency or political subdivision thereof.

 

“Qualified
Financing” means the Offering, provided the Company raises in one or more tranches aggregate gross proceeds of no
less than $6,000,000 pursuant to the Subscription Agreement.

 

“Securities
Act” means the United States Securities Act of 1933, as amended.

 

“Trading
Market” means the OTCQB market place of the OTC Markets; provided however, that in the event the Company’s
Common Stock is ever listed or traded on the New York Stock Exchange, the NYSE Amex Equities, the Nasdaq Global Select Market,
the NASDAQ Global Market, or the NASDAQ Capital Market, then the “Trading Market” shall mean such other market or exchange
on which the Company’s Common Stock is then listed or traded.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a trading
day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted
for trading on a Trading Market and if prices for the Common Stock are then reported on the OTC Markets, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (c) in all other cases, the fair market value of a share of Common Stock as determined by the Board of Directors of the Company
in good faith.

 

    2 

     

    

 

2.       GENERAL
PROVISIONS.

 

2.1       Loss,
Theft, Destruction of Note. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or
mutilation of this Note and, in the case of any such loss, theft or destruction, upon receipt of indemnity or security reasonably
satisfactory to the Company, or, in the case of any such mutilation, upon surrender and cancellation of this Note, the Company
will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Note, a new Note of like tenor and unpaid principal
amount dated as of the date hereof. This Note shall be held and owned upon the express condition that the provisions of this Section
2.1 are exclusive with respect to the replacement of a mutilated, destroyed, lost or stolen Note and shall preclude any and
all other rights and remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to
the replacement of negotiable instruments or other securities without their surrender.

 

2.2       Prepayment;
Redemption. This Note may not be prepaid by the Company in whole or in part, except with the prior written consent of
the Holder. This Note may not be redeemed by the Company in whole or in part, except with the prior written consent of the Holder.

 

3.       CONVERSION
OF NOTE.

 

3.1       Conversion.

 

(a)       Conversion
upon Maturity Date. On the Maturity Date without any action on the part of the Holder, the outstanding principal and accrued
and unpaid interest under the Notes will be converted into shares of New Round Stock based upon a ten percent (10%) discount to
the lesser of (A) the VWAP average of the last 30 calendar days ending on the closing of the Qualified Financing (or, in the event
of multiple closings, the lowest VWAP average of the last 30 calendar days ending on each closing of a Qualified Financing) in
the event of a Maturity Date referred to in clause (b) of the definition thereof, or (B) the VWAP average of the last 30 calendar
days before the Maturity Date in the event of a Maturity Date referred to in clause (a) of the definition thereof (the “Conversion
Price”).

 

(b)       Conversion
upon Change of Control. If a Change of Control transaction occurs prior to the Maturity Date, the outstanding principal and
accrued and unpaid interest under the Note would, at the election of the holders of a majority of the outstanding principal of
the Notes, be either (i) payable upon demand as of the closing of such Change of Control transaction or (ii) convertible into shares
of the Common Stock immediately prior to such Change of Control transaction at a price per share equal to the lesser of (x) the
VWAP average of the last 30 days before the date of consummation of the Change of Control, or (y) the per share consideration to
be received by the holders of the Common Stock in such Change of Control transaction.

 

(c)       Cancellation.
Upon and as of the Maturity Date, this Note will be cancelled on the books and records of the Company and shall solely represent
the right to receive the Conversion Shares.

 

    3 

     

    

 

3.2       Delivery
of Securities Upon Conversion.

 

(a)       As
soon as is practicable after the Maturity Date or an event pursuant to Section 3.1(b)(ii), the Company shall deliver to the Holder
a certificate or certificates evidencing the Conversion Shares issuable to the Holder. Notwithstanding the foregoing and anything
else to the contrary in this Note and the Subscription Agreement, if and to the extent the Company does not have enough authorized
and unreserved shares to issue Common Stock to the holders of notes in the Offering (the “Current Offering Noteholders”),
the Company shall first issue the necessary and applicable shares upon conversion to the Current Offering Noteholders as of the
Maturity Date pursuant to Section 3.1(a), upon the earlier of (i) a reverse stock split of the Company’s Common Stock and
(ii) an increase of the Company’s authorized shares of common stock, in either case which would allow for the issuance of
the shares of Common Stock pursuant to this Note without violating the authorized share number of the Company.

 

(b)       The
issuance of certificates for Conversion Shares upon conversion of this Note shall be made without charge to the Holder for any
issuance tax in respect thereof or other cost incurred by the Company in connection with such conversion and the related issuance
of securities. Upon conversion of this Note, the Company shall take all such actions as are necessary in order to ensure that the
Conversion Shares so issued upon such conversion shall be validly issued, fully paid and nonassessable.

 

3.3       
Fractional Shares. No fractional
shares or scrip representing fractional shares shall be issued upon conversion of this Note. If any conversion of this Note would
create a fractional share or a right to acquire a fractional share, the Company shall round to the nearest whole number.

 

3.4       Anti-Dilution.
In the event the Company consummates a firm commitment, underwritten offering of its common stock by March 27, 2019,
and the price per share thereof (the “Offering Price”) is less than the Conversion Price, then in such
event the Company shall issue to the Holder, at no further cost to the Holder, additional shares of Common Stock equal to the number
of Conversion Shares the Holder would have received upon conversion if the Conversion Price equaled the Offering Price, less the
number of shares of Conversion Shares actually issued on the Maturity Date.

 

4.       STATUS;
RESTRICTIONS ON TRANSFER.

 

4.1       Status
of Note. This Note is a direct, general and unconditional obligation of the Company, and constitutes a valid and legally
binding obligation of the Company, enforceable in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency,
reorganization and other similar laws of general applicability relating to or affecting creditors’ rights and to general
principles of equity. This Note does not confer upon the Holder any right to vote or to consent or to receive notice as a stockholder
of the Company, as such, in respect of any matters whatsoever, or any other rights or liabilities as a stockholder, prior to conversion
hereof into Conversion Shares.

 

    4 

     

    

 

4.2       Restrictions
on Transferability. This Note and any Conversion Shares issued with respect to this Note, have not been registered under
the Securities Act, or under any state securities or so-called “blue sky laws,” and may not be offered, sold, transferred,
hypothecated or otherwise assigned except (a) pursuant to a registration statement with respect to such securities which is effective
under the Act or (b) upon receipt from counsel satisfactory to the Company of an opinion, which opinion is satisfactory in form
and substance to the Company, to the effect that such securities may be offered, sold, transferred, hypothecated or otherwise assigned
(i) pursuant to an available exemption from registration under the Act and (ii) in accordance with all applicable state securities
and so-called “blue sky laws.” The Holder agrees to be bound by such restrictions on transfer. The Holder further consents
that the certificates representing the Conversion Shares that may be issued with respect to this Note may bear a restrictive legend
to such effect. In addition, this Note shall be subject to the restrictions on transfer set forth in Article III of the Subscription
Agreement.

 

4.3       COVENANTS.
In addition to the other covenants and agreements of the Company set forth in this Note, the Company covenants and agrees that
so long as this Note shall be outstanding, if any one or more events occur which constitute or which, with the giving of notice
or the lapse of time or both, would constitute an Event of Default or if the Holder shall demand payment or take any other action
permitted upon the occurrence of any such Event of Default, the Company will forthwith give notice to the Holder, specifying the
nature and status of the Event of Default or other event or of such demand or action, as the case may be.

 

5.       REMEDIES.

 

5.1       Events
of Default. “Event of Default” wherever used herein means any one of the following events:

 

(a)       The
Company shall fail to issue and deliver the Conversion Shares in accordance with Section 3;

 

(b)       Default
in the due and punctual payment of the principal of, or any other amount owing in respect of (including interest), this Note when
and as the same shall become due and payable;

 

(c)       Default
in the performance or observance of any covenant or agreement of the Company in this Note (other than a covenant or agreement a
default in the performance of which is specifically provided for elsewhere in this Section 6.1), and the continuance of
such default for a period of 10 days after there has been given to the Company by the Holder a written notice specifying such default
and requiring it to be remedied;

 

(d)       The
entry of a decree or order by a court having jurisdiction adjudging the Company as bankrupt or insolvent; or approving as properly
filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under the Federal
Bankruptcy Code or any other applicable federal or state law, or appointing a receiver, liquidator, assignee, trustee or sequestrator
(or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up or liquidation
of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 calendar days;

 

    5 

     

    

 

(e)       The
institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution of
bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization
or relief under the Federal Bankruptcy Code or any other applicable federal or state law, or the consent by it to the filing of
any such petition or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator (or other similar official)
of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors;

 

(f)       The
Company seeks the appointment of a statutory manager or proposes in writing or makes a general assignment or an arrangement or
composition with or for the benefit of its creditors or any group or class thereof or files a petition for suspension of payments
or other relief of debtors or a moratorium or statutory management is agreed or declared in respect of or affecting all or any
material part of the indebtedness of the Company; or

 

(g)       It
becomes unlawful for the Company to perform or comply with its obligations under this Note.

 

5.2       Effects
of Default. If an Event of Default occurs and is continuing, then and in every such case the Holder may declare this
Note to be due and payable immediately, by a notice in writing to the Company, and upon any such declaration, the Company shall
pay to the Holder the outstanding principal amount of this Note plus all accrued and unpaid interest through the date the Note
is paid in full.

 

5.3       Remedies
Not Waived; Exercise of Remedies. No course of dealing between the Company and the Holder or any delay in exercising
any rights hereunder shall operate as a waiver by the Holder. No failure or delay by the Holder in exercising any right, power
or privilege under this Note shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other
or further exercise thereof or the exercise of any other right, power or privilege. By acceptance hereof, the Holder acknowledges
and agrees that this Note is one of a series of Convertible Subordinated Promissory Notes of similar tenor issued by the Company
pursuant to the Offering (collectively, the “Related Notes”) and that upon the occurrence and during
the continuance of any Event of Default, the holders of a majority in original principal amount of the Related Notes, including
this Note, shall have the right to act on behalf of the holders of all such Notes in exercising and enforcing all rights and remedies
available to all of such holders under this Note, including, without limitation, foreclosure of any judgment lien on any assets
of the Company. By acceptance hereof, the Holder agrees not to independently exercise any such right or remedy without the consent
of the holders of a majority in original principal amount of the Related Notes.

 

6.       MISCELLANEOUS.

 

6.1       Severability.
If any provision of this Note shall be held to be invalid or unenforceable, in whole or in part, neither the validity nor the enforceability
of the remainder hereof shall in any way be affected.

 

    6 

     

    

 

6.2       Notice.
Where this Note provides for notice of any event, such notice shall be given (unless otherwise herein expressly provided) in writing
and either (a) delivered personally, (b) sent by certified, registered or express mail, postage prepaid or (c) sent by facsimile
or other electronic transmission, and shall be deemed given when so delivered personally, sent by facsimile or other electronic
transmission (confirmed in writing) or mailed. Notices shall be addressed, if to Holder, to its address as provided in the Subscription
Agreement or, if to the Company, to its principal office.

 

6.3       Governing
Law. This Note shall be governed by, and construed in accordance with, the laws of the State of Delaware (without giving
effect to any conflicts or choice of law provisions that would cause the application of the domestic substantive laws of any other
jurisdiction).

 

6.4       Forum.
The Holder and the Company hereby agree that any dispute which may arise out of or in connection with this Note shall be adjudicated
before a court of competent jurisdiction in the State of Delaware and they hereby submit to the exclusive jurisdiction of the courts
of the State of Delaware, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, with respect
to any action or legal proceeding commenced by either of them and hereby irrevocably waive any objection they now or hereafter
may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is
an inconvenient forum.

 

6.5       Headings.
The headings of the Articles and Sections of this Note are inserted for convenience only and do not constitute a part of this Note.

 

6.6       Amendments.
This Note may be amended or waived only with the written consent of the Company and the holders of a majority in original aggregate
principal amount of this Note and the other Related Notes. Any such amendment or waiver shall be binding on all holders of the
Notes, even if they do not execute such consent, amendment or waiver.

 

6.7       No
Recourse Against Others. The obligations of the Company under this Note are solely obligations of the Company and no
officer, employee or stockholder shall be liable for any failure by the Company to pay amounts on this Note when due or perform
any other obligation.

 

6.8       Assignment;
Binding Effect. This Note may be assigned by the Company without the prior written consent of the Holder. This Note
shall be binding upon and inure to the benefit of both parties hereto and their respective permitted successors and assigns.

 

Signature
on the Following Page

 

 

    7 

     

    

 

In
Witness Whereof, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove
written.

 

	 	Bionik Laboratories Corp.	 
	 	 	 
	 	 	 
	 	By:	                          	 
	 	Name: Eric Dusseux	 
	 	Title:   CEO	 

 

    	 	Signature Page to Convertible Promissory NoteExhibit 10.3

 

EXCHANGE AGREEMENT

 

THIS EXCHANGE AGREEMENT
(this “Agreement”) is dated as of the 28th day of June, 2018 (the “Effective Date”),
by and between Bionik Laboratories Corp., a Delaware corporation (the “Company”), and RGD Investissements S.A.S
(the “Holder”).

 

WHEREAS, the Holder
beneficially owns and holds that certain (i) Promissory Note, dated as of April 12, 2018, issued by the Company, in the principal
amount of $420,000 (the “$420K Note”), (ii) Promissory Note, dated as of April 26, 2018, issued by the Company,
in the principal amount of $500,000 (the “$500K Note”), (iii) Promissory Note, dated as of May 10, 2018, issued
by the Company, in the principal amount of $190,000 (the “$190K Note”), (iv) Promissory Note, dated as of May
24, 2018, issued by the Company, in the principal amount of $590,000 (the “$590K Note”), (v) Promissory Note,
dated as of June 12, 2018, issued by the Company, in the principal amount of $100,000 (the “$100K Note”), and
(vi) Promissory Note, dated as of June 22, 2018, issued by the Company, in the principal amount of $160,000 (the “$160K
Note” and, collectively with the $420K Note, the $500K Note, the $190K Note, the $590K Note, and the $100K Note, the
 “Notes”).

 

WHEREAS, the Holder
desires to exchange all of the Notes, including accrued but unpaid interest on the Notes through June 28, 2018, for one of the
Company’s Convertible Promissory Notes (the “Exchange Security”) pursuant to the Company’s convertible
note offering of up to $6,000,000 (the “Offering”), and the Company desires to issue the Exchange Security in
exchange for all of the Notes, all on the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, in
consideration of the terms and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Company and the Holders hereby agree as follows:

 

Section 1. Exchange.
On the Effective Date, subject to and upon the terms and conditions set forth in this Agreement, the Holder shall surrender to
the Company the Notes and all of the rights, covenants, agreements and obligations set forth therein or contemplated thereby, including
but not limited to any interest accrued and unpaid on the principal amount of the Notes (collectively, the “Rights”),
and, in exchange therefore, the Company shall issue to the Holder the Exchange Security, with an issue date as of the Effective
Date. The Exchange Security shall be substantially the same as the convertible promissory notes issued by the Company pursuant
to the Offering. Upon the Effective Date, the Holder will not have any interest or title in or to any of the Notes or the Rights.

 

Section 2. Ownership
and Interest. The Holder is the record and beneficial owner of each of the Notes and the Rights, free and clear of all liens,
charges, pledges, security interests, claims, mortgages, options, encumbrances, rights of first refusal, conditions, covenants,
and other restrictions (other than any restrictions under the Securities Act of 1933, as amended, or state securities laws).

 

Section 3. Applicable
Law. This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware without regard
to its conflict of law rules.

 

     

     

    

 

Section 4. Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if
the signature were an original, not a facsimile signature.

 

Section 5. Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.

 

Section 6. Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

Section 7. Entire
Agreement; Amendments. This Agreement and the Exchange Security supersede all other prior oral or written agreements between
the Holder, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and
this Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters
covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Holder makes any
representation, warranty, covenant or undertaking with respect to such matters; provided, however, that all representations and
warranties contained in that certain Subscription Agreement, dated as of the Effective Date and executed and delivered by the Holder,
shall be incorporated herein. No provision of this Agreement may be amended other than by an instrument in writing signed by the
Company and the Holder. No provision hereof may be waived other than by an instrument in writing signed by the party against whom
enforcement is sought.

 

Section 8. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns. The Holder may not assign any of its rights hereunder without the prior written consent of the Company.

 

Section 9. No Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

Section 10. Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

[Signature Pages
Follow]

 

    2 

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Exchange Agreement as of the date first written above.

 

	 	BIONIK
    LABORATORIES CORP.	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/
    Eric Dusseux	 
	 	Name:  Eric
    Dusseux	 
	 	Title:  CEO	 
	 	 	 	 
	 	 	 	 
	 	RGD
    INVESTISSEMENTS S.A.S	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/
    Remi Gaston-Dreyfus	 
	 	Name:  Remi
    Gaston-Dreyfus	 
	 	Title:
    CEO	 

 

    3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]